Cargando…

FiO(2) Before Surfactant, but Not Time to Surfactant, Affects Outcomes in Infants With Respiratory Distress Syndrome

Aim: To establish the impact of oxygen requirement before surfactant (SF) and time from birth to SF administration on treatment outcomes in neonatal respiratory distress syndrome (RDS). Methods: We conducted a post-hoc analysis of data from a prospective cohort study of 500 premature infants treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruczek, Piotr, Krajewski, Paweł, Hożejowski, Roman, Szczapa, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520978/
https://www.ncbi.nlm.nih.gov/pubmed/34671585
http://dx.doi.org/10.3389/fped.2021.734696
Descripción
Sumario:Aim: To establish the impact of oxygen requirement before surfactant (SF) and time from birth to SF administration on treatment outcomes in neonatal respiratory distress syndrome (RDS). Methods: We conducted a post-hoc analysis of data from a prospective cohort study of 500 premature infants treated with less invasive surfactant administration (LISA). LISA failure was defined as the need for early (<72 h of life) mechanical ventilation (MV). Baseline clinical characteristic parameters, time to SF, and fraction of inspired oxygen (FiO(2)) prior to SF were all included in the multifactorial logistic regression model that explained LISA failure. Results: LISA failed in 114 of 500 infants (22.8%). The median time to SF was 2.1 h (IQR: 0.8–6.7), and the median FiO(2) prior to SF was 0.40 (IQR: 0.35–0.50). Factors significantly associated with LISA failure were FiO(2) prior to SF (OR 1.03, 95% CI 1.01–1.04) and gestational age (OR 0.82, 95 CI 0.75–0.89); both p <0.001. Time to SF was not an independent risk factor for therapy failure (p = 0.528) or the need for MV at any time during hospitalization (p = 0.933). Conclusions: The FiO(2) before SF, but not time to SF, influences the need for MV in infants with RDS. While our findings support the relevance of FiO(2) in SF prescription, better adherence to the recommended FiO(2) threshold for SF (0.30) is required in daily practice.